Mt. Petrucci et al., Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1, ANN HEMATOL, 78(1), 1999, pp. 13-18
Interleukin-6 (IL-6) serum levels and the proliferative activity of bone ma
rrow plasma cells have been described as important prognostic factors for s
urvival duration in multiple myeloma (MM) patients. Since growth of neoplas
tic plasma cells is frequently promoted by IL-6, inhibition of its activity
has been considered for the management of MM patients. With a similar rati
onale, IL-6 variants characterized by wildtype or increased affinity for th
e ligand-specific IL-6 alpha receptor chain and reduced ability to bind and
/or dimerize the gp 130 chain have recently been generated. In the present
study, the antiproliferative effects of the Variants Sant1, Sant5, and Sant
7, characterized by increasing antagonistic activity, were investigated by
means of a detailed cell kinetic and apoptotic analysis of the IL-6-depende
nt MM XG-1 cell line. A significant reduction in the mean percent of XG-1 c
ells in active S-phase (DNA/bromodeoxyuridine incorporation) from 41% to 28
.1% (p=0.04), 25.8% (p=0.04), and 15.3% (p=0.02), respectively, was observe
d using Sant1, Sant5, and Sant7. These effects were confirmed using the acr
idine-orange (AO) flow-cytometric technique, which showed a similar reducti
on of S-phase (34.2% of baseline value) in the presence of Sant1, Sant5, an
d Sant7, as well as a significant G(1b) arrest (from 44.5% to 47.6%, 48%, a
nd 64.9%). Furthermore, IL-6 variants were capable of down-regulating the G
(1) cell cycle regulatory protein cyclin D1 expression. Cell cycle effects
were coupled with a significant increase of apoptosis, measured by the AO a
nd the terminal deoxynucleotidyl transferase assays, from 12.9% (control cu
lture with IL-6) to 21.2% (Sant1), 29.1% (Sant5), and 23.5% (Sant7). These
results were comparable to those obtained by depriving XG-1 of recombinant
IL-6. Our study documents the antiproliferative activity exerted by IL-6 mu
tants on the XG-1 cell line, thus supporting the investigation of these mol
ecules on primary MM cells.